CS209859B2 - Způsob výroby nových derivátů aminokyselin - Google Patents

Způsob výroby nových derivátů aminokyselin Download PDF

Info

Publication number: CS209859B2
Authority: CS; Czechoslovakia
Prior art keywords: formula; compounds; compound; group; effect
Prior art date: 1975-03-26

Application number

CS613178A

Other languages

Czech (cs)

English (en)

Inventor

Laszlo Feuer

Arpad Furka

Ferenc Sebestyen

Jolan Hercsel

Erzsebet Bendefy

Original Assignee

Chinoin Gyogyszer Es Vegyeszet

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-03-26

Filing date

1978-09-22

Publication date

1981-12-31

1978-09-22 Application filed by Chinoin Gyogyszer Es Vegyeszet filed Critical Chinoin Gyogyszer Es Vegyeszet

1981-12-31 Publication of CS209859B2 publication Critical patent/CS209859B2/cs

Links

238000004519 manufacturing process Methods 0.000 title claims description 4
150000001413 amino acids Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 41
238000000034 method Methods 0.000 claims description 16
230000008569 process Effects 0.000 claims description 14
150000003839 salts Chemical class 0.000 claims description 11
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 5
239000001257 hydrogen Substances 0.000 claims description 5
238000003776 cleavage reaction Methods 0.000 claims description 4
230000007017 scission Effects 0.000 claims description 4
229960003080 taurine Drugs 0.000 claims description 4
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 2
ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims description 2
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims description 2
125000006678 phenoxycarbonyl group Chemical group 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims 2
125000001589 carboacyl group Chemical class 0.000 claims 1
238000006243 chemical reaction Methods 0.000 claims 1
229910052736 halogen Inorganic materials 0.000 claims 1
150000002367 halogens Chemical group 0.000 claims 1
-1 phenyloxycarbonyl Chemical group 0.000 claims 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
230000000694 effects Effects 0.000 description 25
239000004480 active ingredient Substances 0.000 description 14
238000002360 preparation method Methods 0.000 description 10
210000003491 skin Anatomy 0.000 description 8
235000019155 vitamin A Nutrition 0.000 description 8
239000011719 vitamin A Substances 0.000 description 8
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 7
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 7
239000013543 active substance Substances 0.000 description 7
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 7
229940045997 vitamin a Drugs 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
230000006378 damage Effects 0.000 description 6
230000000144 pharmacologic effect Effects 0.000 description 6
241000700159 Rattus Species 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
210000000988 bone and bone Anatomy 0.000 description 5
238000005755 formation reaction Methods 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
230000029663 wound healing Effects 0.000 description 5
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
239000002537 cosmetic Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 3
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 3
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
239000003708 ampul Substances 0.000 description 3
239000003674 animal food additive Substances 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
229960004544 cortisone Drugs 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000002674 ointment Substances 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000003449 preventive effect Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
239000011573 trace mineral Substances 0.000 description 3
235000013619 trace mineral Nutrition 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
241000233866 Fungi Species 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
SUZRRICLUFMAQD-UHFFFAOYSA-N N-Methyltaurine Chemical compound CNCCS(O)(=O)=O SUZRRICLUFMAQD-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
206010041591 Spinal osteoarthritis Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
235000013330 chicken meat Nutrition 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
201000001245 periodontitis Diseases 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000005855 radiation Effects 0.000 description 2
208000005801 spondylosis Diseases 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 1
SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
241001164374 Calyx Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
208000003556 Dry Eye Syndromes Diseases 0.000 description 1
206010013774 Dry eye Diseases 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
208000000381 Familial Hypophosphatemia Diseases 0.000 description 1
208000000571 Fibrocystic breast disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010020914 Hypervitaminoses Diseases 0.000 description 1
206010021135 Hypovitaminosis Diseases 0.000 description 1
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
208000001393 Lathyrism Diseases 0.000 description 1
238000005684 Liebig rearrangement reaction Methods 0.000 description 1
208000000185 Localized scleroderma Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010027982 Morphoea Diseases 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
208000007379 Muscle Hypotonia Diseases 0.000 description 1
208000027419 Muscular hypotonia Diseases 0.000 description 1
208000023178 Musculoskeletal disease Diseases 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
241001484645 Ozaena Species 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
206010048979 Sinobronchitis Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
108010042606 Tyrosine transaminase Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
235000019742 Vitamins premix Nutrition 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012042 active reagent Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910001854 alkali hydroxide Inorganic materials 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
150000003973 alkyl amines Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
208000011803 breast fibrocystic disease Diseases 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
229910052793 cadmium Inorganic materials 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000005518 carboxamido group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
210000004081 cilia Anatomy 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
210000000795 conjunctiva Anatomy 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000012043 crude product Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
125000001142 dicarboxylic acid group Chemical group 0.000 description 1
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
206010016629 fibroma Diseases 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000035876 healing Effects 0.000 description 1
229920006158 high molecular weight polymer Polymers 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007803 itching Effects 0.000 description 1
150000003951 lactams Chemical group 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
239000000944 linseed oil Substances 0.000 description 1
235000021388 linseed oil Nutrition 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
239000000463 material Substances 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
239000000155 melt Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000037345 metabolism of vitamins Effects 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
229940023490 ophthalmic product Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940127017 oral antidiabetic Drugs 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
230000000113 radiomimetic effect Effects 0.000 description 1
230000004223 radioprotective effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
238000007142 ring opening reaction Methods 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000002784 sclerotic effect Effects 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
150000003377 silicon compounds Chemical class 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
230000008359 toxicosis Effects 0.000 description 1
230000018889 transepithelial transport Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
230000007332 vesicle formation Effects 0.000 description 1
150000002266 vitamin A derivatives Chemical class 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
235000019168 vitamin K Nutrition 0.000 description 1
239000011712 vitamin K Substances 0.000 description 1
230000001755 vocal effect Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Landscapes

Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CS613178A 1975-03-26 1978-09-22 Způsob výroby nových derivátů aminokyselin CS209859B2 (cs)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU74CI1558A HU174114B (hu)	1975-03-26	1975-03-26	Sposob poluchenija novykh proizvodnykh aminokislot

Publications (1)

Publication Number	Publication Date
CS209859B2 true CS209859B2 (cs)	1981-12-31

Family

ID=10994560

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
CS613178A CS209859B2 (cs)	1975-03-26	1978-09-22	Způsob výroby nových derivátů aminokyselin
CS613578A CS209863B2 (cs)	1975-03-26	1978-09-22	Způsob výroby nových derivátů aminokyselin
CS613278A CS209860B2 (cs)	1975-03-26	1978-09-22	Způsob výroby nových derivátů aminokyselin
CS613478A CS209862B2 (cs)	1975-03-26	1978-09-22	Způsob výroby -L-glutamyltaurinu
CS613378A CS209861B2 (cs)	1975-03-26	1978-09-22	Způsob výroby nových derivátů aminokyselin

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
CS613578A CS209863B2 (cs)	1975-03-26	1978-09-22	Způsob výroby nových derivátů aminokyselin
CS613278A CS209860B2 (cs)	1975-03-26	1978-09-22	Způsob výroby nových derivátů aminokyselin
CS613478A CS209862B2 (cs)	1975-03-26	1978-09-22	Způsob výroby -L-glutamyltaurinu
CS613378A CS209861B2 (cs)	1975-03-26	1978-09-22	Způsob výroby nových derivátů aminokyselin

Country Status (4)

Country	Link
AT (5)	AT357999B (de)
CS (5)	CS209859B2 (de)
HU (1)	HU174114B (de)
PL (4)	PL106656B1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU185632B (en) *	1981-03-27	1985-03-28	Chinoin Gyogyszer Es Vegyeszet	New process for preparing gamma-glutamyl-taurine

1975
- 1975-03-26 HU HU74CI1558A patent/HU174114B/hu unknown
- 1975-04-29 PL PL19680375A patent/PL106656B1/pl unknown
- 1975-04-29 PL PL19680475A patent/PL102866B1/pl unknown
- 1975-04-29 PL PL19679975A patent/PL108619B1/pl unknown
- 1975-04-29 PL PL19680075A patent/PL106523B1/pl unknown
1977
- 1977-08-30 AT AT625077A patent/AT357999B/de not_active IP Right Cessation
- 1977-08-30 AT AT625277A patent/AT358549B/de not_active IP Right Cessation
- 1977-08-30 AT AT625477A patent/AT358000B/de not_active IP Right Cessation
- 1977-08-30 AT AT625177A patent/AT353768B/de not_active IP Right Cessation
1978
- 1978-07-24 AT AT534178A patent/AT358550B/de not_active IP Right Cessation
- 1978-09-22 CS CS613178A patent/CS209859B2/cs unknown
- 1978-09-22 CS CS613578A patent/CS209863B2/cs unknown
- 1978-09-22 CS CS613278A patent/CS209860B2/cs unknown
- 1978-09-22 CS CS613478A patent/CS209862B2/cs unknown
- 1978-09-22 CS CS613378A patent/CS209861B2/cs unknown

Also Published As

Publication number	Publication date
AT357999B (de)	1980-08-11
ATA625277A (de)	1980-02-15
AT358000B (de)	1980-08-11
CS209860B2 (cs)	1981-12-31
CS209862B2 (cs)	1981-12-31
PL106656B1 (pl)	1980-01-31
PL106523B1 (pl)	1979-12-31
AT353768B (de)	1979-12-10
ATA625077A (de)	1980-01-15
CS209863B2 (cs)	1981-12-31
ATA625177A (de)	1979-05-15
CS209861B2 (cs)	1981-12-31
AT358550B (de)	1980-09-10
ATA625477A (de)	1980-01-15
PL102866B1 (pl)	1979-04-30
PL108619B1 (en)	1980-04-30
AT358549B (de)	1980-09-10
ATA534178A (de)	1980-02-15
HU174114B (hu)	1979-11-28

Publication	Publication Date	Title
JPS6152147B2 (de)	1986-11-12
HU199440B (en)	1990-02-28	Process for producing morpholine derivatives and pharmaceutical compositions comprising the compounds
CS209858B2 (en)	1981-12-31	Method of making the new derivatives of the aminoacids
JPS6011024B2 (ja)	1985-03-22	新規アミノ酸誘導体の製法
EP0561597B1 (de)	1997-01-02	Physostigmin-Derivate, ihre Verwendung und sie enthaltende pharmazeutische Formulierungen
CS209859B2 (cs)	1981-12-31	Způsob výroby nových derivátů aminokyselin
DE69509091T2 (de)	1999-09-09	Salze von 2-[(2,6-dichlorophenyl)amin]phenylacetoxyessigsäure mit organischen basischen kationen
US3985878A (en)	1976-10-12	Anti-inflammatory and antirheumatic compounds and preparation
CA2019749C (en)	2002-02-05	[.alpha.-(tert.butyl aminomethyl)-3,4-dichlorobenzyl] thioacetamide, a procedure for its preparation and its uses
US4419367A (en)	1983-12-06	Stimulant
JP2011162536A (ja)	2011-08-25	ビタミンｅ誘導体を有効成分とする鎮痛剤
JPH10218767A (ja)	1998-08-18	骨疾患治療剤
SE440908B (sv)	1985-08-26	2-(o-karboxifenylamino)-6h-pyrimido(2,1-b)kinazol-6-on och derivat derav och kompositioner derav
JP2006213611A (ja)	2006-08-17	１‐アミノシクロプロパンカルボン酸等を主成分とする脳卒中又は脳卒中後遺症の予防用又は治療用薬剤